Integrin-mediated augmentation of antigenic immunity
Author & Article Information
Authors: Upendra Marathi, PhD1, Yared Hailemichael, PhD2, Nandadeva Lokugamage3, Michael Schotsaert4, Angela Choi4, Imran Chwdhury3, Nisha Garg3, Adolfo Garcia-Sastre4, Lionel Lewis1, Siddhartha De1, Peter Vanderslice, PhD5, Jeffrey Actor6, Darren Woodside, PhD5
Associations: 1 7 Hills Pharma, Houston, TX, United States; 2 M.D. Anderson Cancer Center, Houston, TX, United States ; 3 The University of Texas Medical Branch, Galveston, TX, United States ; 4 Ichan School of Medicine at Mount Sinai, New York, NY, United States ; 5 Texas Heart Institute, Houston, TX, United States ; 6 UT Health, Houston, TX, United States
Correspondence: Darren Woodside (dwoodside@texasheart.org)
Abstract
The use of immune stimulatory agents as systemic drugs to augment adjuvantation can be problematic due to elevated risks of toxicity and non-specific immune responses. Integrins αLβ2/ICAM-1 and α4β1/VCAM-1 are essential for antigen-specific immune responses. [1,2] In particular, these integrins stabilize receptor-mediated cell adhesion between Antigen Presenting Cells and naïve CD4+ T cells, providing a co-stimulatory signal required for effective antigen presentation.[3] 7HP349 is a first-in-concept, orally bioavailable, positive allosteric activator of these integrins.
See the original article here | The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting